Hepatic late adverse effects after antineoplastic treatment for childhood cancer.
CONCLUSIONS: The prevalence of hepatic late adverse effects among studies with an adequate outcome definition varied considerably from 1% to 53%. Evidence suggests that radiotherapy involving the liver, higher BMI, chronic viral hepatitis and longer follow-up time or older age at follow-up increase the risk of hepatic late adverse effects. In addition, there may be a suggestion that busulfan, thioguanine, hepatic surgery, higher alcohol intake (>14 units per week), metabolic syndrome, use of statins, non-Hispanic white ethnicity, and older age at cancer diagnosis increase the risk of hepatic late adverse effects. High-quality studies are needed to evaluate the effects of different therapy doses, time trends, and associated risk factors after antineoplastic treatment for childhood cancer.
PMID: 30985922 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Mulder RL, Bresters D, Van den Hof M, Koot BG, Castellino SM, Loke YKK, Post PN, Postma A, Szőnyi LP, Levitt GA, Bardi E, Skinner R, van Dalen EC Tags: Cochrane Database Syst Rev Source Type: research
More News: Alcoholism | Bilirubin | Cancer | Cancer & Oncology | Chemotherapy | Childhood Cancer | Cholesterol | Conferences | Databases & Libraries | General Medicine | Hematology | Hepatitis | Hepatitis C | Liver | Metabolic Syndrome | Pediatrics | PET Scan | Statin Therapy | Study | Urology & Nephrology